The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

Pharmacogenetics

Volumn 14, Issue 3, 2004, Pages 147-154

  Haufroid, Vincent ^a,c,d   Mourad, Michel ^b   Van Kerckhove, Valérie ^a   Wawrzyniak, Jeremie ^a   De Meyer, Martine ^b   Eddour, Djamila Chaib ^b   Malaise, Jacques ^b   Lison, Dominique ^a   Squifflet, Jean Paul ^b   Wallemacq, Pierre ^c  

^a Indust and Environ Toxicology Unit   (Belgium)

^b Kidney and Pancreas Transplant Unit   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cyclosporine; CYP3A5; MDR1 (ABCB1); Polymorphisms; Tacrolimus; Transplantation

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ALLELE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MULTIDRUG RESISTANCE; MULTIPLE REGRESSION; PRIORITY JOURNAL;

COHORT STUDIES; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 12144286933     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200403000-00002     Document Type: Article

References (30)

1. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29:404-430.
2. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47:1048-1052.
3. Chowbay B, Cumaraswany S, Cheung YB, Zhou Q, Lee EJD. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13:89-95.
4. MacPhee IAM, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotain correlate with dose requirement. Transplantation 2002; 74:1486-1489.
5. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3:477-483.
6. Anglicheau D, Vertuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14:1889-1896.
7. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43:555-564.
8. Kuzuya T, Kobayashi T, Moriyama N, Nagasaka T, Yokoyama I, Uchida K, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 2003; 76:865-868.
9. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-254.
10. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233-1235.
11. Hustert E, Haberl M, Burk O, Wolbold R, He Y-Q, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
12. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 27:383-391.
13. Lee SJ, Usmani KA, Ghanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13:461-472.
14. Kim RB. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12:425-427.
15. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43:630-635.
16. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20:753-761.
17. Zanger UM. Role of genetic polymorphism, drug exposure and sex for expression and function of hepatic cytochromes P450. Thirteenth International Conference on Cytochromes P450 Biochemistry, Biophysics and Drug Metabolism, 29 June to 3 July 2003. Prague, Czech Republic.
18. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080.
19. Fromm MF. Genettically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002 181-182:299-303.
20. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43:285-307.
21. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
22. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
23. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31:309-316.
24. Wallemacq PE, Alexandre K. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays. Clin Chem 1999; 45:432-435.
25. Wallemacq PE, Leal T, Besse T, Squifflet JP, Reding R, Otte JB, et al. IMx tacrolimus II vs. IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients. Clin Chem 1997; 43:1989-91.
26. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002; 12:331-334.
27. Tanabe T, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
28. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221.
29. Balram C, Sharma A, Sivathasan C, Lee EJD. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 2003; 56:78-83.
30. Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O, et al. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 2003; 304:745-752.